← Back to Home

Sarclisa Subcutaneous Formulation Wins FDA Approval, Moving Cancer Treatment Toward Wearable Drug Delivery

The shift of a multiple myeloma drug from intravenous infusion to subcutaneous injection is not merely a convenience upgrade; it pushes the long administration times, in-hospital resources, and patient burden in cancer care to a starting point for redesign.

By SURL BioNews

For many cancer patients, treatment does not happen only at the moment a drug enters the body. It also takes place in the long gaps spent waiting for infusions, traveling to and from the hospital, enduring administration-related reactions, and arranging daily life. The U.S. FDA’s approval of Sanofi’s Sarclisa Escena subcutaneous formulation allows this multiple myeloma drug to be administered through an on-body injector, marking a shift in how anticancer antibody drugs are used, from traditional infusion rooms toward lighter care workflows.

Sanofi said Sarclisa Escena has been approved in the United States for use in combination with standard treatment regimens, covering the multiple myeloma indications already approved in the United States for the existing intravenous version of Sarclisa. The company also said it is the first anticancer treatment that can be administered through an on-body injector, while it can also be given manually by healthcare professionals as a subcutaneous injection. Fierce Pharma also focused on this point, noting that the approval makes Sarclisa the first cancer drug administered in an on-body injector form.

Sarclisa’s active ingredient is isatuximab, a monoclonal antibody targeting CD38, used in the treatment of multiple myeloma. Drugs of this type have traditionally relied largely on intravenous infusion, requiring clinic time, staffing, and patient chair time. After the shift to subcutaneous administration, the focus is not only a change in route of administration, but the possibility that the entire treatment setting may move closer to a model that is schedulable, predictable, and less dependent on infusion chairs. However, this remains a prescription anticancer treatment, and administration and monitoring do not mean leaving the medical system.

The key evidence supporting the approval comes from IRAKLIA, a Phase 3 non-inferiority study. Sanofi previously announced that the trial enrolled 531 patients with relapsed or refractory multiple myeloma across 252 trial sites worldwide, evaluating the Sarclisa subcutaneous formulation administered using Enable Injections’ enFuse hands-free on-body delivery system and comparing it with intravenous Sarclisa in combination with pomalidomide and dexamethasone.

In the results announced by Sanofi, the objective response rate for subcutaneous Sarclisa combined with Pd was 71.1%, compared with 70.5% for intravenous Sarclisa combined with Pd, meeting the non-inferiority objective. The study also met the co-primary endpoint of steady-state trough concentration. The company also said the subcutaneous group had fewer systemic administration-related reactions. These data support the formulation switch without sacrificing key efficacy measures, but the publicly available summaries remain limited. Full safety data, differences in convenience across patient populations, and the pace of adoption in clinical practice will still depend on more complete data and institutional workflows.

This approval also reflects hematologic cancer treatment entering another level of competition. As multiple myeloma now has multiple antibody, immunomodulatory drug, proteasome inhibitor, and cell therapy options, drugs are competing not only on efficacy curves, but also on administration burden, care efficiency, and whether patients can maintain treatment over the long term. For Sanofi, Sarclisa Escena is expected to extend the life cycle of an existing product. For healthcare systems, the real test is how to turn convenience into executable improvements in care without compromising safety monitoring.

References

  1. Fierce Pharma
  2. Sanofi
  3. Sanofi